Corporate Presentation
October 2025

> SLEEP DIAGNOSTICS & TREATMENT
> NEURO DIAGNOSTICS
> BRAIN RESEARCH
> ULTRASONIC BLOOD FLOW MONITORING
> MEDICAL INNOVATIONS

OVER 30 YEARS OF EXCELLENCE IN DIAGNOSTICS

Business Snapshot

Compumedics (ASX: CMP) is a leading global medical technology company focused on sleep, neurological disorders and ultrasonic brain blood flow monitoring.

#1 — Technology developer/leader in Compumedics' respective end markets, with **over 30,000 systems** installed worldwide to date

Australia based, with wholly owned offices in the **USA, Germany, France, Austria and Korea** and a network of 100+ distributors globally

ASX — Long track record, having been **founded in 1987** and listed on the ASX since 2000

Global team comprised of **~180 people** across 6 countries

$52M — Generated **$51m of revenue** in FY25. Revenue guidance of A$70M+ and EBITDA of ~A$9M in FY26

Compumedics has a number of leading market positions

#1 — **Australian** Sleep and neuro diagnostics supplier

******* — **Japan** Sleep and neuro diagnostics supplier

#1 — **China** Sleep diagnostics device supplier to premier facilities (and #1 TCD supplier)

#1 — **Germany** TCD Supplier

#3 — **USA** Sleep diagnostics device supplier and emerging #3 supplier for neurological monitoring devices

B2B business model with leading blue-chip customer base

- Compumedics **sells directly** to end-user customers in Australia, USA, France and Germany and through its network of **more than 100 distributors** to all other parts of the world
- Key customers include hospitals, doctors/clinics, universities and research organisations

NASA MAYO CLINIC NIH National Institutes of Health UNIVERSITY OF OXFORD The Royal Children's Hospital Melbourne EINSTEIN Albert Einstein College of Medicine Yale University School of Medicine PEKING UNIVERSITY Stanford MEDICINE TMDU

Executive Summary

Delivering Record Revenues and Scalable Growth Across Global Healthcare Markets

Record Sales Orders

$63.4M

Up +22% on FY24

Up +49% on FY23

Record Sales Revenue

$51.0M

Up +2% on FY24, +15% excl MEG

Up +20% on FY23

EBITDA

$2.9M

Up +9% on FY24

Major Contract Wins

- **Best Med $5M p.a. over 4-years:** multi-year SaaS + disposables contract
- **Phillips $3M over 5-years:** Australian pharmacy-based HST program leveraging Somfit platform
- **Virtuox $3M p.a. over 5-years:** national U.S. sleep diagnostics rollout
- **Persante $3M over 3-years:** leading U.S. sleep provider signed for Somfit platform

Core Priorities

- **U.S. expansion accelerating** across sleep, neurology, and research segments
- **Somfit SaaS gaining traction** in U.S., EU & AU markets
- **Three MEG orders progressing**, and scheduled for FY26 delivery
- **DWL transformation** to enable profitable, scalable growth
- **U.S. install base driving recurring revenue** from consumables and customer care
- **EBITDA uplift delivered** through scale, mix optimisation, and cost discipline

Growth Drivers

- **Drive Growth Across All Segments** by scaling SaaS, hardware, and consumables, and converting Somfit, MEG, and Care into recurring revenue engines
- **Expand Global Footprint** through deeper U.S. penetration and strategic growth across Europe and Asia via partners and distribution
- **Invest in Next Leg of Growth** by launching Somfit-D and robotic TCD, backed by continued investment in R&D, systems, and leadership scale-up
- **Unlock Transformational Upside** with Somfit SaaS (~$250M to $10B) and OrionMEG® LifeSpan (~$13.6B) long-term market potential

Board and Management

Experienced, Visionary Leadership Driving Innovation, Growth, and Global Market Expansion

Strengthened Executive Team

1. **Strengthened executive team** in FY25 with targeted hires supporting U.S. commercial expansion, Somfit SaaS, and Falcon sales growth.

Additional Appointments

2. **FY26** plans include **additional non-executive appointments** to bolster governance and strategic execution.

Deep Operational Capability

3. **Deep operational capability** built across finance, sales, and delivery functions to drive performance and enable succession planning for long-term scale.

Invested In Systems

4. **Invested in systems**, processes, and reporting to enhance transparency, execution, and scalability across global operations.

Embedded Performance

5. **Embedded performance discipline and accountability,** aligned to growth priorities in Sleep, SaaS, Neurology and Brain Research.

FY25 Financial Performance

FY25 Financial Results

Compumedics is delivering strong growth supported by multiple growth opportunities and disciplined cost control

Sales Orders ($M)

Record sales orders FY25 up +22% YoY



Sales Revenue ($M)

Record sales revenue FY25 up +3% YoY



USA Sales Orders ($M)

Record USA sales orders up +118% YoY



Somfit & SaaS Sales Orders ($M)

Record Somfit & SaaS Revenue: 11% of total revenue (9% in FY24)



EBITDA ($M)

EBITDA: $2.9M (margin expansion in H2 FY25)



Key Takeaways

Compumedics Performance

- CMP produced YoY growth across all major financial metrics in FY25
- H2 FY25 performance provides baseline run rate to target material earnings growth in FY26

Market Overview & Performance

- Strong tailwinds across sleep, neurology, and neuroimaging markets
- Rising global demand for home-sleep-test (HST) diagnostics and SaaS-enabled solutions
- MEG and TCD gaining traction as next-gen brain & stroke diagnostics
- Strategic markets (USA, China, EU) recovering post-COVID with strong growth
- Compumedics gaining share in high-margin, high-tech segments

FY25 Financial Performance

Compumedics produced YoY growth across all major financial metrics in FY25

Financial Performance

30 June FYE | $M	FY23A	FY24A	FY25A	FY26F
Sales Orders	**42.5**	**51.9**	**63.4**	**75.0**
Growth YoY	*+12%*	*+22%*	*+22%*	*+18%*
Revenue Reported	**42.4**	**49.7**	**51.0**	**70.0**
Growth YoY	*+12%*	*+17%*	*+4%*	*+37%*
Gross Profit	**21.6**	**26.0**	**30.9**	**37.8**
Gross Margin	*51%*	*52%*	*61%*	*54%*
EBITDA	**-2.0**	**2.7**	**2.9**	**9.0**
EBITDA Margin	*-5%*	*5%*	*6%*	*13%*

FY25 Highlights:

- **Record Sales Orders:** $63.4M, up +22% YoY
- **Record Revenue:** $51.0M, up +3% YoY
- **Gross Profit:** $30.9M, margin increased to 61%, driven by product mix
- **EBITDA:** $2.9M, margin increased to 6%, driven by product mix and scale offsetting investment in the U.S. sales and marketing

Key Drivers:

- **Strong global sleep performance** with record growth across Somfit SaaS, hardware, and consumables
- **U.S. investment delivering results** from focused sales and marketing driving traction in high-growth HST segment
- **Key contract wins** secured multi-year agreements with leading sleep providers underpin continued momentum
- **Margin uplift achieved** through disciplined cost control and favourable product mix driving scalable EBITDA growth

FY26 Outlook:

- **Revenue:** $70.0M (+37% YoY)
- **EBITDA:** $9.0M (13% EBITDA Margin)

Business Model and Revenue Diversification

Diversified revenue base across multiple geographies and segments

Geography

USA:

- Core growth driver with sleep and neuro acceleration

Europe:

- New Somfit and MEG opportunities, neuro wins and DWL rebound

Asia:

- China MEG expansion and large sleep distribution contracts

Australia:

- Somfit pharmacy partnership driving growth

Latin America & Middle East:

- Targeted distributor expansion

Segment

Sleep & SaaS:

- High-end PSG systems + rapidly scaling Somfit SaaS platform
- Clinical-grade, cloud-connected, and built for the shift to home sleep testing

Neuro Monitoring & Research:

- World-first wireless EEG (Okti) and MEG brain analysis systems
- Trusted by neurologists & researchers tackling epilepsy, autism, and brain injury

Bloodflow & TCD:

- DWL systems for real-time brain blood flow monitoring
- Next-gen robotic TCD opens door to AI-driven stroke diagnostics

Consumables & Customer Care:

- Recurring revenue from electrodes, disposables, and support
- Sticky, scalable, and critical to SaaS ecosystem performance





Segment Performance & Outlook

Segment Overview & Performance

Compumedics' technology is focused on the fast growing, high value sleep diagnostics market and the associated fields of neuro-diagnostics and brain research

Sleep & SaaS ($M)	FY24	FY25	YoY%
Sales Orders	16.1	30.2	+88%
Revenue Reported	17.4	24.2	+39%

- U.S. launch of Somfit HST with $3M+ in revenue and $10M pipeline
- Somfit & SaaS revenues to approach 50% of Sleep revenues by FY27
- $24M 4-year with sleep diagnostics distributor in Asia
- $3M 5-year pharmacy channel agreement signed with Philips in AU

Neuro Monitoring & Research ($M)	FY24	FY25	YoY%
Sales Orders	22.7	21.0	(7%)
Revenue Reported	19.0	14.3	(25%)

- MEG System at TJNU successfully installed in FY24
- $15M in new MEG systems to be reported in FY26 ($5M FY24 | Nil FY25)
- Scalable global opportunity as MEG indications expand
- Okti wireless EEG gaining traction in neurology clinics

Bloodflow & TCD DWL ($M)	FY24	FY25	YoY%
Sales Orders	4.7	4.5	(4%)
Revenue Reported	4.4	4.7	+7%

- Recovery underway post-China regulatory delays
- AI robotic TCD development at commercialisation stage
- Targeting stroke, TBI, and neuro ICU with autonomous probe tech
- Partner discussions active to accelerate go-to-market

Consumables & Customer Care ($M)	FY24	FY25	YoY%
Sales Orders	8.4	7.7	(8%)
Revenue Reported	8.3	7.8	(6%)

- Steady annuity-style revenue from global installed base
- Supporting growing SaaS client base with hardware and disposables
- Positioned for incremental margin improvement from scale
- Enables stickiness and recurring value from broader platform

Sleep & SaaS

SaaS-Driven Sleep Diagnostics Leadership: High-Growth Momentum, Scalable Model, Global Traction

Business	% FY25 Sales Orders	Growth & Strategic Highlights	Market Positioning & Opportunity	Example Products / Solutions (Not Exhaustive)
Sleep: Clinical Diagnostics COMPUMEDICS Sleep	46%	• Strong growth from installed base of 25,000+ system • Market share of 30–40% in high-end sleep diagnostics • Long-term partnership with Philips to drive recurring sales • Global channel scale and 35+ years of sleep R&D	• World leader in sleep diagnostics hardware • Comprehensive offering from full PSG systems to portable solutions • Trusted by hospitals, sleep labs, and specialists globally	 **Grael:** Full PSG systems for clinical sleep testing
Somfit & Nexus 360 SaaS Somfit profusion nexus 360 Laboratory Management System	13%	• FY25 revenue \$6.7M (up +49% YoY) • \$3M p.a. agreement with Philips AU • U.S. launch: \$3M revenue to date with \$10M pipeline • Targeting 100K+ Somfit units over 5 years • Somfit & SaaS to reach ~50% of Sleep revenue by FY27	• USA HST market growing ~25% p.a., underpinned by 60M to 80M undiagnosed Americans • Somfit targets a \$150M to \$300M p.a. U.S. HST market • Upside: ~\$250M U.S. reimbursement, ~\$1B global reimbursement • Consumer health potential ~\$1B to \$10B with tech partners • Rapidly scaling cloud-based platform • Enhancing device connectivity, monitoring, and remote diagnostics • Recurring revenue stream with strong margin profile	 **Somfit / Somfit Pro:** Wearable diagnostic devices  **Nexus 360:** Web-based lab & patient management

Neuro Monitoring & Research

Pioneering Neurotech with Scalable MEG Growth and Global Clinical Traction

Business	% FY25 Sales Orders	Growth & Strategic Highlights	Market Positioning & Opportunity	Example Products / Solutions (Not Exhaustive)
Neuro - Clinical Monitoring (non-MEG) Compumedics Neuroscience	15%	• Wireless Okti EEG adoption expanding • Neurology lab footprint growing in EU & U.S. • Strong cross-sell potential with MEG and Sleep • Platform integration opportunities across diagnostics	• Trusted clinical solutions for epilepsy and neurology • Full suite of EEG systems, amplifiers, recorders • Alternative to Natus/Micromed in key markets	 **Okti:** High-definition wireless EEG  **Quik-Cap Arrays:** EEG electrodes Neuroscience Lab Suite
Brain - Research Compumedics Neuroscan	14%	• Neuroscan used in 1,500+ universities/labs across 40+ countries • Advanced analytics driving neuroscience research • Broad R&D appeal: cognitive, sensory, sleep research	• Leading provider of research-grade EEG systems • Highly defensible segment with long-term customer base • Scalable product suite supporting top-tier research	 **CURRY:** Multimodal neuroimaging platform **Neuroscan:** Research EEG amplifiers and software
MEG Orion Lifespan MEG	12%	• FY24 MEG revenue: $4.7M • $15M+ orders for delivery in FY26 • TJNU China site now live, three more systems in pipeline • Market acceleration providing further growth opportunity	• Expansion into paediatric MEG lifts near-term opportunity to ~$120M p.a. • High-growth MRI alternative • Long-term upside: OrionMEG® LifeSpan could scale to ~$13.6B if adoption follows MRI trajectory • Expanding in U.S., EU, and China with major centres	 **Orion Lifespan™ MEG:** Superior functional imaging with unmatched temporal resolution

Bloodflow & TCD (DWL)

AI-Driven TCD Innovation: Commercial Momentum in a $12B Stroke Market

Business	% FY25 Sales Orders	Growth & Strategic Highlights	Market Positioning & Opportunity	Example Products / Solutions (Not Exhaustive)
Bloodflow & TCD (DWL)	9%	• FY25 revenue of $4.5M (typically ~$6M) with growth resuming post-China regulatory resolution • Relaunch of Ez-Dop targeting premium hospital market • Robotic TCD platform advancing toward commercialisation within 12–24 months • Targeting large unmet needs in stroke, TBI, and neuro ICU markets • Strategic partner discussions underway to fast-track commercial deployment	• Positioned to disrupt a $12B+ global stroke diagnostics market with real-time, non-invasive blood flow imaging • Robotic AI-enhanced TCD offers scalable point-of-care solution with minimal operator dependency • Compumedics DWL has a strong brand presence in neurology and neurocritical care globally	 **DWL AI Robotic TCD Prototype:** Portable module that supports use in various positions.

Consumables & Customer Care

High-Margin Recurring Revenue Powering Platform Stickiness and Scale

Business	% FY25 Sales Orders	Growth & Strategic Highlights	Market Positioning & Opportunity	Example Products / Solutions (Not Exhaustive)
Consumables & Customer Care (NeuroMedical Supplies)	15%	• FY25 revenue of $7.8M, underpinned by global installed base • Strong annuity-style revenue stream supporting enterprise-wide recurring model • Supply chain optimised for scalable throughput and cost efficienc • Expansion of hardware and support aligned to growing SaaS install base	• High-margin, predictable revenue stream supporting SaaS lifecycle value • Somfit D unlocks large-scale disposable opportunity linked to 100K+ device units • Consumables model increases customer lifetime value and retention across modalities • Platform enables leverage into broader wellness and diagnostics services ecosystem	**Okti® Child Disposable Backpack** Wearable, single-use EEG harness  **AutoRep Electronic Pipetter** High-precision lab consumable for fluid management 

Asset Management

Asset Management

Building a Scalable Global Leader in Sleep, Neuro, and Brain Health Diagnostics

Investment Highlights

- Deeply embedded global healthcare technology platform
- Leading positions in sleep, neuro, and brain flow monitoring
- High-growth SaaS business model scaling globally
- Breakout product innovation: MEG, Somfit, and AI TCD
- Commercial traction underway in high-value markets
- Compelling value proposition with clear path to scale

Technology & Pipeline

- Somfit-D (disposable HST device) to launch in FY26
- Expanding into CRO/pharma, cardiology, and diabetes monitoring
- Full-stack sleep health SaaS platform
- DWL robotic TCD nearing commercialisation – step-change opportunity
- Continued R&D investment (forecast $10M for FY26) to maintain innovation leadership in all core segments

1. Leading provider of sleep and neuro diagnostics
2. Diversified operations across 3 core verticals (sleep diagnostics, neuro diagnostics / research and brain blood flow monitoring)
3. Supported by significant market opportunities (notably in the US)
4. Leading market positions in core markets including #1 in Australia for sleep and neuro diagnostics supplies with ~80% market share
5. High quality, blue-chip customer base supported by multiple channels to market e.g. Philips, National Institute of Health (USA), The Mayo Clinic (USA), NASA (US) etc.
6. Portfolio of company-developed products provide significant competitive advantage, with ~12% of revenue p.a. dedicated to R&D into new products / IP
7. Manufacture directly and via 3rd parties, at facilities in Australia, Germany, Austria and Korea. New SMT production line launched in 2023, reducing reliance on contract manufacturers and enhancing overall supply chain efficiency
8. Actively growing recurring revenue base (with ~16% from recurring services / supplies and ~12% related to SaaS style revenues)
9. Track record of delivering growth (revenue CAGR of ~15% between FY22 and FY24), with a number of growth opportunities being actively pursued including market / geographic expansion and new product development
10. High quality management team that has long tenure and deep familiarity with the business (incl. Executive Chairman / CEO who is also founder)

Growth & Outlook

Growth & Outlook

2HFY25 financial performance and record orders and run rate provides a baseline target for FY26

Growth Opportunities

Continued **expansion in the USA** across all products (e.g. currently ~80% of people with a sleep disorder go undiagnosed in the US, significant market potential for Compumedics).

Continued **growth in Somfit SaaS** revenues, notably in the USA (fastest growing HST market segment).

Continued **geographical expansion** (incl. Somfit expansion into Europe).

Continued strong **momentum of MEG orders**.

New product development (e.g. Somfit D (disposable) being released to US market in mid FY25).

Continued development of **DWL's new AI robotic TCD offering** (providing additional value-add analytics on top of DWL's world-class precision TCD technology).

FY26 Target

- Revenue growth of +37% YoY to **$70.0M**
- Sustained EBITDA to **$9.0M** and continued margin expansion
- Path to consistent profitability and positive free cash flow

Short to Medium Term

- **Launch Somfit-D in U.S.** and scale commercial uptake across sleep clinics and providers
- **Build MEG orders** and leverage strong global pipeline
- **Drive margin uplift** through disciplined cost control, product mix shift, and operational leverage

Long Term

- **Transformational Upside:** Somfit SaaS (U.S. HST market growing ~25% p.a., underpinned by 60 to 80M undiagnosed Americans; ~$250M U.S. reimbursement; ~$1B global reimbursement; ~$1B to $10B consumer health) and OrionMEG® LifeSpan (~$13.6B if MRI adoption trajectory repeats)
- **Build full-stack SaaS platform** for sleep health with integrated diagnostics and remote care
- **Commercialise AI-enabled robotic TCD** to transform brain monitoring precision
- **Expand into new verticals** including pharma, cardiology, and metabolic health with recurring revenue focus

Disclaimer

This presentation has been prepared by Compumedics Limited (CMP).

While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estimates, opinions or other information contained in the presentation.

This presentation may contain forward looking statements. These forward-looking statements have been made based upon CMP's expectations and beliefs concerning future developments and their potential effect on CMP (and its controlled entities) and are subject to risks and uncertainty which are, in many instances, beyond CMP's control. No assurance is given that future developments will be in accordance with CMP's expectations. Actual results could differ materially from those expected by CMP.

This presentation does not constitute an offer to sell or a solicitation of an offer to purchase any security or financial product or service. Any such offer or solicitation shall be made only pursuant to a Product Disclosure Statement, Information Memorandum, Prospectus or other offer document relating to a financial product or service.

Past performance is not necessarily indicative of future results and no person guarantees the performance of any financial product or service or the amount or timing of any return from it. There can be no assurance that the financial product or service will achieve any targeted return, that asset allocations will be met or that the financial product or service will be able to implement its investment strategy and investment approach or achieve its investment objective.

The information contained in this presentation is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular investment needs.

Thank You

COMPUMEDICS®

> SLEEP DIAGNOSTICS & TREATMENT
> NEURO DIAGNOSTICS
> BRAIN RESEARCH
> ULTRASONIC BLOOD FLOW MONITORING
> MEDICAL INNOVATIONS

OVER 30 YEARS OF EXCELLENCE IN DIAGNOSTICS